Gopinath v. Somalogic, Inc.

District Court, S.D. California·Decided August 21, 2023·No. 3:23-cv-01164·Unknown

Opinion

ASHWIN GOPINATH, Case No.: 23-cv-1164-W-WVG

Plaintiff, ORDER GRANTING IN PART v. AND DENYING IN PART SOMALOGIC, INC.’S MOTION SOMALOGIC, INC., a Delaware TO DISMISS PLAINTIFF’S corporation; and DOES 1 through 20, inclusive, PRAYER FOR EXEMPLARY AND PUNITIVE DAMAGES Defendants. [DOC. 7]

Pending before the Court is Defendant SomaLogic, Inc.’s Motion To Dismiss Plaintiff’s Complaint and Strike Prayer for Exemplary and Punitive Damages (the “Motion”) [Doc. 7]. The Court decides the matter on the papers submitted and without oral argument. See Civ. R. 7.1(d)(1). For the following reasons, the Court GRANTS IN PART and DENIES IN PART SomaLogic’s Motion [Doc. 7]. Plaintiff Dr. Gopinath, cofounded Palamedrix, Inc. (“Palamedrix”) and served as Chief Technology Officer for the company. (Compl. [Doc. 12] ¶¶ 17, 19.) In 2021, the Defendant in this case, SomaLogic, Inc. (“SomaLogic”), approached Palamedrix to discuss a potential merger. (Id. ¶¶ 18, 22.) After about one year of negotiations, SomaLogic and Palamedrix entered into a merger agreement on July 25, 2022 (“Merger Agreement”). (Id. ¶ 25.) Under the Merger Agreement, SomaLogic agreed to pay $35 million upon closing of the merger, comprising $14 million cash (“Upfront Cash Consideration”) and $21 million in SomaLogic common stock (“Upfront Stock Consideration”). (Id. ¶ 26.) The Upfront Stock Consideration was divided between Dr. Gopinath and Palamedrix’s other Founders. (Id.) SomaLogic also agreed to pay up to an additional $17.5 million in “Milestone Consideration” to the Founders if SomaLogic achieved certain revenue-based milestones by 2027 and 2028. (Id. ¶ 33.) Under the Merger Agreement, a Founder is not eligible to receive this additional consideration unless the Founder “remains a full-time employee” with SomaLogic when the milestones are achieved. (Id. ¶ 34.) In connection with the Merger Agreement, SomaLogic provided Dr. Gopinath with a Founder Side Letter Agreement, dated July 25, 2022 (“Founder Side Letter”). (Id. ¶ 27.) Under the Founder Side Letter, Dr. Gopinath’s Upfront Stock Consideration was “fully vested ‘subject to the risk of forfeiture[.]’” (Id. ¶¶ 27–29.) The Founder Side Letter provides that Dr. Gopinath would automatically forfeit certain percentages of the Upfront Stock Consideration if he left SomaLogic before the 12- month, 24-month, or 36-month anniversaries of the merger’s closing. (Id. ¶ 28.) But if Dr. Gopinath resigned for “Good Reason” (or was terminated without “Cause”), then his Upfront Stock Consideration would “no longer be subject to forfeiture.” (Id. ¶ 29.) The Merger Agreement defines “Good Reason” to include “a material, adverse change in [a] Founder’s title, authority, duties or responsibilities.” (Id. ¶ 30.) SomaLogic’s merger with Palamedrix successfully closed on August 31, 2022. (Id. ¶ 25.) After the merger, Dr. Gopinath joined SomaLogic as Senior Director, Assay Development and reported to Dr. Shane Bowen. (Id. ¶ 35.) As required by the parties’ agreements, SomaLogic paid Dr. Gopinath his portion of the Upfront Stock Consideration upon closing, comprising millions of dollars in compensation. (Id. ¶¶ 26, 32.) Issues between Dr. Gopinath and SomaLogic quickly piled up. Dr. Gopinath alleges that “SomaLogic [] prevented former Palamedrix employees from continuing their research and development” and “ma[de] it unnecessarily difficult for former Palamedrix employees to buy even the most basic supplies for research.” (Id. ¶ 43.) He further alleges that SomaLogic’s Vice President of Technology Development, Shane Bowen, “harasses, demeans, and discriminates against SomaLogic’s female employees.” (Id. ¶ 45.) In an interview with SomaLogic’s Senior Vice President of People & Culture, Alison Roelke, Dr. Gopinath “confirmed that Mr. Bowen engaged in inappropriate behavior.” (Id. ¶ 46.) According to Dr. Gopinath, “SomaLogic’s bungling of the Palamedrix acquisition, its mismanagement of former Palamedrix employees, and its promotion of Mr. Bowen led most of Dr. Gopinath’s team from Palamedrix to quit.” (Id. ¶ 51.) This included four of Dr. Gopinath’s six reports. (Id. ¶ 6.) Dr. Gopinath alleges that the “loss of former Palamedrix employees substantially impaired Dr. Gopinath’s ability to execute his duties and responsibilities and achieve the Milestones.” (Id. ¶ 54.) Furthermore, “SomaLogic impeded Dr. Gopinath’s attempts to replace these former Palamedrix employees” and “did not provide Dr. Gopinath with the budget to hire a complete and qualified team needed to achieve the Milestones.” (Id. ¶ 55–56.) Less than three months after the merger closed, in November 2022, Dr. Gopinath “notified SomaLogic that he had Good Reason to resign.” (Id. ¶ 58.) “In response, Dr. Gopinath was banned from SomaLogic’s offices.” (Id. ¶ 59.) A few months later, Dr. Gopinath emailed SomaLogic’s Board of Directors to report that he had “faced problematic behavior from [his] chain of command and HR[.]” (Id. ¶ 68.) Dr. Gopinath “reported Mr. Bowen’s unethical and unlawful conduct to SomaLogic’s Board of Directors” and expressed his concern that “there is a systemic problem with the Somalogic culture and leadership.” (Id. ¶¶ 67, 71.) According to Dr. Gopinath, when he tried to address these issues with SomaLogic leadership he “was immediately asked to work remotely, given vague tasks with unclear instructions, and asked to create an IP paper trail that could create issues for Somalogic, for which [he] would likely be blamed later.” (Id. ¶ 70.) In response to Dr. SomaLogic’s email, “SomaLogic revoked Dr. Gopinath’s access to SomaLogic’s systems and his SomaLogic email account.” (Id. ¶ 73.) About a month later, Dr. Gopinath “resigned” from his position at SomaLogic when he emailed notice of “his resignation” to several SomaLogic executives. (Id. ¶ 75.) In that email, Dr. Gopinath stated that his resignation was “effective immediately.” (Id.) Later that day, SomaLogic sent him a “termination letter” that “purport[ed]” to “terminate[]” his employment with SomaLogic “effective immediately.” (Id. ¶ 77.) SomaLogic brought this motion on June 29, 2023. SomaLogic’s first argument in the Motion was that the Complaint should be dismissed under the forum non conveniens doctrine based on the Forum Selection Clause in the Employment Agreement between the Parties. (Mot. at 6.) On July 27, 2023, while this motion was pending, SomaLogic informed Dr. Gopinath that it was “withdrawing its forum non conveniens argument.” (See Decl. of R. Taylor [Doc. 13-1] at 1.) In its Reply, SomaLogic withdrew the forum non conveniens argument reflected in Section III.A of the Motion. (Reply [Doc. 15] at 2, n. 1.) SomaLogic’s other arguments as to its motion to dismiss and motion to strike remain. A. Legal Standard Federal Rule of Civil Procedure 12(b)(6) allows a defendant to file a motion to dismiss for failing “to state a claim upon which relief can be granted.” Fed. R. Civ. P. 12(b)(6). A motion to dismiss under Rule 12(b)(6) tests the complaint’s sufficiency. See N. Star Int’l v. Ariz. Corp. Comm’n., 720 F. 2d 578, 581 (9th Cir. 1983). A complaint may be dismissed as a matter of law either for lack of a cognizable legal theory or for insufficient facts under a cognizable theory. Balisteri v. Pacifica Police Dep’t., 901 F.2d 696, 699 (9th Cir. 1990). In ruling on the motion, a court must “accept all material allegations of fact as true and construe the complaint in a light most favorable to the non- moving party.” Vasquez v. L.A. Cnty., 487 F. 3d 1246, 1249 (9th Cir. 2007). To survive a motion to dismiss, a complaint must contain “a short and plain statement of the claim showing that the pleader is entitled to relief.” Fed. R. Civ. P.

Gopinath v. Somalogic, Inc., (S.D. Cal. 2023).

Gopinath v. Somalogic, Inc. (Gopinath v. Somalogic, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Papasan v. Allain
478 U.S. 265 (Supreme Court, 1986)
Fogerty v. Fantasy, Inc.
510 U.S. 517 (Supreme Court, 1994)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Whittlestone, Inc. v. Handi-Craft Co.
618 F.3d 970 (Ninth Circuit, 2010)
Fantasy, Inc. v. Fogerty
984 F.2d 1524 (Ninth Circuit, 1993)
Michael Lacey v. Joseph Arpaio
693 F.3d 896 (Ninth Circuit, 2012)
Stevenson v. Superior Court
941 P.2d 1157 (California Supreme Court, 1997)
Green v. Ralee Engineering Co.
960 P.2d 1046 (California Supreme Court, 1998)
Tameny v. Atlantic Richfield Co.
610 P.2d 1330 (California Supreme Court, 1980)
Alvarez v. Hill
518 F.3d 1152 (Ninth Circuit, 2008)
In Re TFT-LCD (Flat Panel) Antitrust Litigation
586 F. Supp. 2d 1109 (N.D. California, 2008)
Lee v. BANK OF AMERICA NATIONAL TRUST AND SAVINGS ASS'N
27 Cal. App. 4th 197 (California Court of Appeal, 1994)
Clark v. Allstate Insurance
106 F. Supp. 2d 1016 (S.D. California, 2000)
Ferrick v. Santa Clara University
231 Cal. App. 4th 1337 (California Court of Appeal, 2014)
Tamara Moore v. Mars Petcare US, Inc.
966 F.3d 1007 (Ninth Circuit, 2020)
Sprewell v. Golden State Warriors
266 F.3d 979 (Ninth Circuit, 2001)
Rees v. PNC Bank, N.A.
308 F.R.D. 266 (N.D. California, 2015)
Ivy v. Diamond Shamrock Chemicals Co.
901 F.2d 7 (Second Circuit, 1990)